Brighi, N.; Lamberti, G.; Andrini, E.; Mosconi, C.; Manuzzi, L.; Donati, G.; Lisotti, A.; Campana, D.
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Curr. Oncol. 2023, 30, 1381-1394.
https://doi.org/10.3390/curroncol30020106
AMA Style
Brighi N, Lamberti G, Andrini E, Mosconi C, Manuzzi L, Donati G, Lisotti A, Campana D.
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current Oncology. 2023; 30(2):1381-1394.
https://doi.org/10.3390/curroncol30020106
Chicago/Turabian Style
Brighi, Nicole, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, and Davide Campana.
2023. "Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors" Current Oncology 30, no. 2: 1381-1394.
https://doi.org/10.3390/curroncol30020106
APA Style
Brighi, N., Lamberti, G., Andrini, E., Mosconi, C., Manuzzi, L., Donati, G., Lisotti, A., & Campana, D.
(2023). Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current Oncology, 30(2), 1381-1394.
https://doi.org/10.3390/curroncol30020106